Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis

Blood

Volumn 96, Issue 4, 2000, Pages 1525-1530

  Roboz, G J ^a   Dias, S ^a   Lam, G ^a   Lane, W J ^a   Soignet, S L ^a   Warrell R P , Jr ^a   Rafii, S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; VASCULOTROPIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENDOTHELIUM; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0034663032     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.4.1525     Document Type: Article

References (37)

1. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
2. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
3. 3) in the treatment of acute promyelocytic leukemia (APL), II: Clinical efficacy and pharmacokinetics in relapsed patients
4. Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia
5. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia
6. U.S. multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL)
7. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells
8. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
9. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases
10. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells
11. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells
12. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML/RARα independent manner
13. 3 exerts dose-dependent dual effects on APL cells
14. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines
15. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
16. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: Activation of caspases and down-regulation of Bcl-2 protein
17. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms
18. Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type 1-transformed cells
19. Effect of arsenic trioxide on viability, proliferation and apoptosis in human megakaryocytic leukemia cell lines
20. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
21. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro
22. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression
23. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
24. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
25. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
26. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
27. Increased angiogenesis in chronic myeloid leukemia and myelodysplastic syndromes
28. Angiogenesis in myelodysplastic syndromes: Analysis of 59 cases
29. Clinical applications of research on angiogenesis
30. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors
31. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
32. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
33. Culture of human endothelial cells derived from umbilical veins: Identification by morphologic and immunologic criteria
34. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro
35. Role of laminin and basement membrane in the morphological differentiation of the human endothelial cells into capillary-like structures
36. Activation-dependent alpha5beta1 integrin-mediated adhesion to fibronectin decreases proliferation of chronic myelogenous leukemia progenitors and K562 cells
37. Vascular endothelial growth factor (VEGF) and its receptors